Summary
In osteoporosis, calcitonin exerts an analgesic effect that is unrelated to its effect on bone. Although the precise mechanism has yet to be clarified, there is some evidence that the analgesic effect of calcitonin may be mediated through the endogenous opioid system. The intranasal administration of calcitonin seems to be more effective in producing analgesia than parenteral administration.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melzach R, Wall PD (1965) Pain mechanisms: A new theory. Science 150:971–978
Gennari C (1981) Calcitonin and bone metastases of cancer. In: Pecile A (ed) Calcitonin 1980. Excerpta Medica. Amsterdam, pp 277–287
Gennari C, Chierichetti SM, Gonnelli S, Vibelli C, Montagnani M, Piolini M (1986) Migraine prophylaxis with salmon calcitonin: A cross-over double blind placebo-controlled study. Headache 26:13–16
Minaire P, Mallet E, Levernieux J, Schoutens A, Attali G, Caulin F (1987) Immobilization bone loss: Preventive effect of calcitonin in several clinical modules. In: Christiansen C et al (eds) Osteoporosis 1987. Osteopress, Copenhagen, p 603
Attali G, Levernieux J, Caulin F (1987) Recent crush fracture syndrome. Effect of salmon calcitonin. Results of three double blind studies and one open study. In: Christiansen C et al (eds) Osteoporosis 1987. Osteopress. Copenhagen, pp 930–932
Arinoviche R, Arriagada M, Jacobelli S, et al. (1987) Calcitonin in acute pain due to vertebral fractures in osteoporosis. Rev Med Chile 115:1039–1043
Levernieux J, Julien D, Caulin F (1986) The effect of calcitonin on bone pain and acute resorption related to recent osteoporotic crush fractures: Results of a double-blind and an open study. In: Cecchettin M et al (eds) Calciotropic Hormones and Calcium Metabolism. Elsevier, Amsterdam, pp 171–178
Bordier P, Kuntz D, Miravet L, Marie P (1979) Treatment of primary osteoporosis by the combination of salmon calcitonin, phosphorus and magnesium, Nouv Presse Med 8:444
Ringe JD, Welzel D (1987) Salmon calcitonin in the therapy of corticoid induced osteoporosis. Eur J Clin Pharm 33:35–39
Gennari C (1983) Clinical aspects of calcitonin in pain. Triangle 22:157–163
Tschoipp FA, Henke H, Petermann JB, et al. (1985) Calcitonin gene-related peptide and its binding sites in the human central nervous system and pituitary. Proc Natl Acad Sci USA 92:248–252
Laurian L, Oberman Z, Graf E, Gilad S, Hoerer E, Simantov R (1986) Calcitonin induced increase in ACTH, β-endorphin and cortisol secretion. Horm Metabol Res 18:268–271
Gennari C, Agnusdei D, Gonnelli S, et al. (1990), Confirmation of the analgesic efficacy of Miacalcic nasal in the treatment of postmenopausal osteoporosis. In: Peck WA (ed) Prevention of Postmenopausal Osteoporosis, Dream or Reality?Parthenon Publishing, Carnforth, pp 65–74
Pun KK, Chan LWL (1989) Analgesic effect of intranasal salmon calcitonin in the treatment of osteoporotic vertebral fractures. Clin Ther 11:205–209
Pontiroli AE, Alberetto M, Calderara A, et al. (1986) Human calcitonin administered by the nasal route: Bioavailability of different formulations and efficacy in postmenopausal osteoporosis. Life Sci 125:249–253
Gennari C, Agnusdei D, Gonnelli S, et al. (1990) Bone pain in osteoporosis. In: Nordin BEC (ed) Osteoporosis Contribution to Modern Management. Parthenon Publishing, Carnforth, pp 57–64
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gennari, C., Agnusdei, D. & Camporeale, A. Use of calcitonin in the treatment of bone pain associated with osteoporosis. Calcif Tissue Int 49 (Suppl 2), S9–S13 (1991). https://doi.org/10.1007/BF02561370
Issue Date:
DOI: https://doi.org/10.1007/BF02561370